Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

The FDA on April 26 approved Pfizer Inc.’s Beqvez (fidanacogene elaparvovec-dzkt) as a prophylactic treatment for adults with moderate to severe hemophilia B. Beqvez could become the new standard of care for hemophilia B, since it can prevent serious bleeding for up to three years after one dose is administered. Per Pfizer’s press release on the approval, the current standard of care “requires regular intravenous infusions…often administered multiple times a week or multiple times a month.” Pfizer will price a single course of Beqvez at $3.5 million before patient assistance and rebates, according to press reports. Norstella’s Evaluate Pharma projects the drug will net $57 million in global sales this year, following its July launch, growing to $378 million by 2030.

From Evaluate Pharma

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 14

Datapoint: Sandoz Reaches Agreement With Amgen to Launch Prolia, Xgeva Biosimilars

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 13

Datapoint: Utilization Trend Fuels $80M Operating Loss for UCare

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today